Table 1.
Baseline characteristics of 26 patients treated with tildrakizumab.
| Characteristics | n (%)/mean±SD |
|---|---|
| Men | 14 (53.8) |
| Age (years) | 56±16 |
| Bodyweight (kg) | 75±16 |
| BMI (kg/m2) | 26.4±5.9 |
| Psoriasis duration (years) | 11.9±8.3 |
| Psoriatic arthritis | 5 (19.2) |
| Obesity | 4 (15.4) |
| Diabetes | 2 (7.7) |
| Hypercholesterolaemia | 5 (19.2) |
| Hypertension | 12 (46.2) |
| Previous systemic therapy | 26 (100) |
| Previous biologic therapy | 5 (19.2) |
| Psoriasis Area and Severity Index (PASI) | 12.5±6.5 |
| Physician’s Global Assessment (PGA) | 2.6±1 |
| Dermatology Life Quality Index (DLQI) | 15.9±4 |